Literature DB >> 23162605

Conducting the G-protein Coupled Receptor (GPCR) Signaling Symphony in Cardiovascular Diseases: New Therapeutic Approaches.

Stephen L Belmonte1, Burns C Blaxall.   

Abstract

G protein-coupled receptors (GPCRs) are a virtually ubiquitous class of membrane-bound receptors, which functionally couple hormone or neurotransmitter signals to physiological responses. Dysregulation of GPCR signaling contributes to the pathophysiology of a host of cardiovascular disorders. Pharmacological agents targeting GPCRs have been established as therapeutic options for decades. Nevertheless, the persistent burden of cardiovascular diseases necessitates improved treatments. To that end, exciting drug development efforts have begun to focus on novel compounds that discriminately activate particular GPCR signaling pathways.

Entities:  

Year:  2012        PMID: 23162605      PMCID: PMC3496286          DOI: 10.1016/j.ddmod.2012.03.001

Source DB:  PubMed          Journal:  Drug Discov Today Dis Models        ISSN: 1740-6757


  79 in total

Review 1.  Beta-3 adrenoceptors as new therapeutic targets for cardiovascular pathologies.

Authors:  Chantal Gauthier; Bertrand Rozec; Boris Manoury; Jean-Luc Balligand
Journal:  Curr Heart Fail Rep       Date:  2011-09

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 3.  Hemodynamic and neurohumoral evidence of multifaceted pathophysiology in human hypertension.

Authors:  S Julius
Journal:  J Cardiovasc Pharmacol       Date:  1990       Impact factor: 3.105

Review 4.  The 7 TM G-protein-coupled receptor target family.

Authors:  Edgar Jacoby; Rochdi Bouhelal; Marc Gerspacher; Klaus Seuwen
Journal:  ChemMedChem       Date:  2006-08       Impact factor: 3.466

5.  Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis.

Authors:  E O Weinberg; F J Schoen; D George; Y Kagaya; P S Douglas; S E Litwin; H Schunkert; C R Benedict; B H Lorell
Journal:  Circulation       Date:  1994-09       Impact factor: 29.690

6.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

Authors:  M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

7.  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

Authors: 
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

8.  Dual action of angiotensin II on coronary resistance in the isolated perfused rabbit heart.

Authors:  I Pörsti; M Hecker; E Bassenge; R Busse
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-12       Impact factor: 3.000

9.  Targeting G protein-coupled receptor kinases (GRKs) in Heart Failure.

Authors:  Henriette Brinks; Walter J Koch
Journal:  Drug Discov Today Dis Mech       Date:  2010

Review 10.  Interactions between the sympathetic nervous system and the RAAS in heart failure.

Authors:  Steven R Goldsmith
Journal:  Curr Heart Fail Rep       Date:  2004-07
View more
  3 in total

Review 1.  Targeting the 26S Proteasome To Protect Against Proteotoxic Diseases.

Authors:  Natura Myeku; Karen E Duff
Journal:  Trends Mol Med       Date:  2017-12-09       Impact factor: 11.951

Review 2.  Regulating the regulators: Epigenetic, transcriptional, and post-translational regulation of RGS proteins.

Authors:  Mohammed Alqinyah; Shelley B Hooks
Journal:  Cell Signal       Date:  2017-10-16       Impact factor: 4.315

Review 3.  Engineering therapeutic antibodies targeting G-protein-coupled receptors.

Authors:  Migyeong Jo; Sang Taek Jung
Journal:  Exp Mol Med       Date:  2016-02-05       Impact factor: 8.718

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.